BioMarin Pharmaceutical Management
Management criteria checks 3/4
BioMarin Pharmaceutical's CEO is Alexander Hardy, appointed in Dec 2023, has a tenure of 2.08 years. total yearly compensation is $14.85M, comprised of 7.1% salary and 92.9% bonuses, including company stock and options. directly owns 0.017% of the company’s shares, worth $1.93M. The average tenure of the management team and the board of directors is 2.1 years and 2.1 years respectively.
Key information
Alexander Hardy
Chief executive officer
US$14.9m
Total compensation
| CEO salary percentage | 7.07% |
| CEO tenure | 2.1yrs |
| CEO ownership | 0.02% |
| Management average tenure | 2.1yrs |
| Board average tenure | 2.1yrs |
Recent management updates
Recent updates
BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight
Dec 26Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts
Oct 30
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 06Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Jul 22Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment?
Apr 27The Price Is Right For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Mar 31The Strong Earnings Posted By BioMarin Pharmaceutical (NASDAQ:BMRN) Are A Good Indication Of The Strength Of The Business
Mar 04BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Feb 21BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy
Jan 23Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call
Nov 21BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
Aug 21BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
Jul 24BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain
May 15BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$520m |
| Jun 30 2025 | n/a | n/a | US$657m |
| Mar 31 2025 | n/a | n/a | US$524m |
| Dec 31 2024 | US$15m | US$1m | US$427m |
| Sep 30 2024 | n/a | n/a | US$322m |
| Jun 30 2024 | n/a | n/a | US$257m |
| Mar 31 2024 | n/a | n/a | US$205m |
| Dec 31 2023 | US$19m | US$65k | US$168m |
Compensation vs Market: Alexander's total compensation ($USD14.85M) is about average for companies of similar size in the US market ($USD13.36M).
Compensation vs Earnings: Alexander's compensation has been consistent with company performance over the past year.
CEO
Alexander Hardy (57 yo)
Mr. Alexander Hardy serves as President, Chief Executive Officer & Director of BioMarin Pharmaceutical Inc. since December 01, 2023 having joined in December 2023. He had been Chief Executive Officer at Ge...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.1yrs | US$14.85m | 0.017% $ 1.9m | |
| CFO & Executive VP | 6yrs | US$5.50m | 0.052% $ 5.9m | |
| Executive VP | 22yrs | US$5.06m | 0.043% $ 4.9m | |
| Executive VP & Chief Commercial Officer | 1.7yrs | US$6.93m | 0.0014% $ 158.3k | |
| Executive VP and Chief Research & Development Officer | 1.3yrs | US$7.22m | 0.023% $ 2.6m | |
| Executive VP & CTO | no data | US$5.70m | 0.032% $ 3.6m | |
| Chief Scientific Officer & Senior VP of Research and Early Development | no data | no data | no data | |
| Executive VP & Chief People Officer | 7yrs | no data | no data | |
| Senior Vice President of Technical Development | 4.3yrs | no data | no data | |
| Executive VP & Chief Corporate Affairs Officer | 2yrs | no data | no data | |
| Executive VP & Chief Business Officer | 1.3yrs | no data | no data | |
| Group Vice President | no data | no data | no data |
Experienced Management: BMRN's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.1yrs | US$14.85m | 0.017% $ 1.9m | |
| Independent Chairman of the Board | 19.1yrs | US$719.07k | 0.063% $ 7.1m | |
| Independent Director | 2.1yrs | US$461.17k | 0.0011% $ 127.8k | |
| Director | less than a year | no data | no data | |
| Independent Director | 9.5yrs | US$463.05k | 0.014% $ 1.6m | |
| Independent Director | less than a year | no data | 0.00022% $ 24.9k | |
| Independent Director | 4.9yrs | US$467.05k | 0.011% $ 1.3m | |
| Independent Director | 8.3yrs | US$467.05k | 0.016% $ 1.8m | |
| Independent Director | 2.1yrs | US$445.05k | 0.0011% $ 127.8k | |
| Independent Director | 6.5yrs | US$463.55k | 0.012% $ 1.4m | |
| Independent Director | 2.1yrs | US$461.17k | 0.0011% $ 128.9k |
Experienced Board: BMRN's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 12:16 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioMarin Pharmaceutical Inc. is covered by 51 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Ying Huang | Barclays |
| Huidong Wang | Barclays |